Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma

Xinlong Ma, Koji Yoshimoto, Yaulei Guan, Nobuhiro Hata, Masahiro Mizoguchi, Noriaki Sagata, Hideki Murata, Daisuke Kuga, Toshiyuki Amano, Akira Nakamizo, Tomio Sasaki

研究成果: ジャーナルへの寄稿記事

42 引用 (Scopus)

抄録

The subclassification of glioblastoma (GBM) into clinically relevant subtypes using microRNA (miRNA)- and messenger RNA (mRNA)-based integrated analysis has been attempted. Because miRNAs regulate multiple gene-signaling pathways, understanding miRNA-mRNA interactions is a prerequisite for understanding glioma biology. However, such associations have not been thoroughly examined using high-throughput integrated analysis. To identify significant miRNA-mRNA correlations, we selected and quantified signature miRNAs and mRNAs in 82 gliomas (grade II: 14, III: 16, IV: 52) using real-time reverse-transcriptase polymerase chain reaction. Quantitative expression data were integrated into a single analysis platform that evaluated the expression relationship between miRNAs and mRNAs. The 21 miRNAs include miR-15b, -21, -34a, -105, -124a, -128a, -135b, -184, -196a-b, -200a-c, -203, -302a-d, -363, -367, and -504. In addition, we examined 23 genes, including proneural markers (DLL3, BCAN, and OLIG2), mesenchymal markers (YKL-40, CD44, and Vimentin), cancer stem cell-related markers, and receptor tyrosine kinase genes. Primary GBM was characterized exclusively by upregulation of mesenchymal markers, whereas secondary GBM was characterized by significant downregulation of mesenchymal markers, miR-21, and -34a, and by upregulation of proneural markers and miR-504. Statistical analysis showed that expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM. Our functional analysis of miR-128a and -504 as inhibitors demonstrated that suppression of miR-128a and -504 increased the expression of mesenchymal markers in glioblastoma cell lines. Mesenchymal signaling in GBM may be negatively regulated by miR-128a and -504.

元の言語英語
ページ(範囲)1153-1162
ページ数10
ジャーナルNeuro-Oncology
14
発行部数9
DOI
出版物ステータス出版済み - 9 1 2012

Fingerprint

Glioblastoma
MicroRNAs
Gene Expression
Messenger RNA
Glioma
Up-Regulation
Genes
Neoplastic Stem Cells
Receptor Protein-Tyrosine Kinases
Vimentin
Reverse Transcriptase Polymerase Chain Reaction
Real-Time Polymerase Chain Reaction
Down-Regulation
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

これを引用

Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. / Ma, Xinlong; Yoshimoto, Koji; Guan, Yaulei; Hata, Nobuhiro; Mizoguchi, Masahiro; Sagata, Noriaki; Murata, Hideki; Kuga, Daisuke; Amano, Toshiyuki; Nakamizo, Akira; Sasaki, Tomio.

:: Neuro-Oncology, 巻 14, 番号 9, 01.09.2012, p. 1153-1162.

研究成果: ジャーナルへの寄稿記事

Ma, X, Yoshimoto, K, Guan, Y, Hata, N, Mizoguchi, M, Sagata, N, Murata, H, Kuga, D, Amano, T, Nakamizo, A & Sasaki, T 2012, 'Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma', Neuro-Oncology, 巻. 14, 番号 9, pp. 1153-1162. https://doi.org/10.1093/neuonc/nos145
Ma, Xinlong ; Yoshimoto, Koji ; Guan, Yaulei ; Hata, Nobuhiro ; Mizoguchi, Masahiro ; Sagata, Noriaki ; Murata, Hideki ; Kuga, Daisuke ; Amano, Toshiyuki ; Nakamizo, Akira ; Sasaki, Tomio. / Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. :: Neuro-Oncology. 2012 ; 巻 14, 番号 9. pp. 1153-1162.
@article{fa96e4ff6a0141e2aa1c8319fa2e1869,
title = "Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma",
abstract = "The subclassification of glioblastoma (GBM) into clinically relevant subtypes using microRNA (miRNA)- and messenger RNA (mRNA)-based integrated analysis has been attempted. Because miRNAs regulate multiple gene-signaling pathways, understanding miRNA-mRNA interactions is a prerequisite for understanding glioma biology. However, such associations have not been thoroughly examined using high-throughput integrated analysis. To identify significant miRNA-mRNA correlations, we selected and quantified signature miRNAs and mRNAs in 82 gliomas (grade II: 14, III: 16, IV: 52) using real-time reverse-transcriptase polymerase chain reaction. Quantitative expression data were integrated into a single analysis platform that evaluated the expression relationship between miRNAs and mRNAs. The 21 miRNAs include miR-15b, -21, -34a, -105, -124a, -128a, -135b, -184, -196a-b, -200a-c, -203, -302a-d, -363, -367, and -504. In addition, we examined 23 genes, including proneural markers (DLL3, BCAN, and OLIG2), mesenchymal markers (YKL-40, CD44, and Vimentin), cancer stem cell-related markers, and receptor tyrosine kinase genes. Primary GBM was characterized exclusively by upregulation of mesenchymal markers, whereas secondary GBM was characterized by significant downregulation of mesenchymal markers, miR-21, and -34a, and by upregulation of proneural markers and miR-504. Statistical analysis showed that expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM. Our functional analysis of miR-128a and -504 as inhibitors demonstrated that suppression of miR-128a and -504 increased the expression of mesenchymal markers in glioblastoma cell lines. Mesenchymal signaling in GBM may be negatively regulated by miR-128a and -504.",
author = "Xinlong Ma and Koji Yoshimoto and Yaulei Guan and Nobuhiro Hata and Masahiro Mizoguchi and Noriaki Sagata and Hideki Murata and Daisuke Kuga and Toshiyuki Amano and Akira Nakamizo and Tomio Sasaki",
year = "2012",
month = "9",
day = "1",
doi = "10.1093/neuonc/nos145",
language = "English",
volume = "14",
pages = "1153--1162",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma

AU - Ma, Xinlong

AU - Yoshimoto, Koji

AU - Guan, Yaulei

AU - Hata, Nobuhiro

AU - Mizoguchi, Masahiro

AU - Sagata, Noriaki

AU - Murata, Hideki

AU - Kuga, Daisuke

AU - Amano, Toshiyuki

AU - Nakamizo, Akira

AU - Sasaki, Tomio

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The subclassification of glioblastoma (GBM) into clinically relevant subtypes using microRNA (miRNA)- and messenger RNA (mRNA)-based integrated analysis has been attempted. Because miRNAs regulate multiple gene-signaling pathways, understanding miRNA-mRNA interactions is a prerequisite for understanding glioma biology. However, such associations have not been thoroughly examined using high-throughput integrated analysis. To identify significant miRNA-mRNA correlations, we selected and quantified signature miRNAs and mRNAs in 82 gliomas (grade II: 14, III: 16, IV: 52) using real-time reverse-transcriptase polymerase chain reaction. Quantitative expression data were integrated into a single analysis platform that evaluated the expression relationship between miRNAs and mRNAs. The 21 miRNAs include miR-15b, -21, -34a, -105, -124a, -128a, -135b, -184, -196a-b, -200a-c, -203, -302a-d, -363, -367, and -504. In addition, we examined 23 genes, including proneural markers (DLL3, BCAN, and OLIG2), mesenchymal markers (YKL-40, CD44, and Vimentin), cancer stem cell-related markers, and receptor tyrosine kinase genes. Primary GBM was characterized exclusively by upregulation of mesenchymal markers, whereas secondary GBM was characterized by significant downregulation of mesenchymal markers, miR-21, and -34a, and by upregulation of proneural markers and miR-504. Statistical analysis showed that expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM. Our functional analysis of miR-128a and -504 as inhibitors demonstrated that suppression of miR-128a and -504 increased the expression of mesenchymal markers in glioblastoma cell lines. Mesenchymal signaling in GBM may be negatively regulated by miR-128a and -504.

AB - The subclassification of glioblastoma (GBM) into clinically relevant subtypes using microRNA (miRNA)- and messenger RNA (mRNA)-based integrated analysis has been attempted. Because miRNAs regulate multiple gene-signaling pathways, understanding miRNA-mRNA interactions is a prerequisite for understanding glioma biology. However, such associations have not been thoroughly examined using high-throughput integrated analysis. To identify significant miRNA-mRNA correlations, we selected and quantified signature miRNAs and mRNAs in 82 gliomas (grade II: 14, III: 16, IV: 52) using real-time reverse-transcriptase polymerase chain reaction. Quantitative expression data were integrated into a single analysis platform that evaluated the expression relationship between miRNAs and mRNAs. The 21 miRNAs include miR-15b, -21, -34a, -105, -124a, -128a, -135b, -184, -196a-b, -200a-c, -203, -302a-d, -363, -367, and -504. In addition, we examined 23 genes, including proneural markers (DLL3, BCAN, and OLIG2), mesenchymal markers (YKL-40, CD44, and Vimentin), cancer stem cell-related markers, and receptor tyrosine kinase genes. Primary GBM was characterized exclusively by upregulation of mesenchymal markers, whereas secondary GBM was characterized by significant downregulation of mesenchymal markers, miR-21, and -34a, and by upregulation of proneural markers and miR-504. Statistical analysis showed that expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM. Our functional analysis of miR-128a and -504 as inhibitors demonstrated that suppression of miR-128a and -504 increased the expression of mesenchymal markers in glioblastoma cell lines. Mesenchymal signaling in GBM may be negatively regulated by miR-128a and -504.

UR - http://www.scopus.com/inward/record.url?scp=84867500546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867500546&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nos145

DO - 10.1093/neuonc/nos145

M3 - Article

C2 - 22844109

AN - SCOPUS:84867500546

VL - 14

SP - 1153

EP - 1162

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 9

ER -